10,000 people could benefit from new migraine drug
Fremanezumab, a new drug preventing chronic migraine, has been recommended in final draft guidance from National Institute for health and Care Excellence (NICE) today (12 March 2020) following clinical trials based on research led by King’s College London.
By NIHR Maudsley BRC at 12 Mar 2020